In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated: Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone
Tesamorelin & Ipamorelin, research compound, third party tested, COA available, Disguised Alpha, Freeze Dried Isolates Tesamorelin & Ipamorelin is commonly positioned around GHRH analog research, growth-hormone secretory pathway studies, endocrine signaling models
Author Disclaimer Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense
May 2025: Post-marketing research suggests that GLP-1s like Ozempic are associated with an increased risk of deep vein thrombosis (a type of blood clot)
Diabetes Weight Management Achieve More in Diabetic Weight Management with GLP-1 RA Expert Endocrine Care Providing top-notch care to patients with endocrine disorders
( Pharmaceuticals , 2026) reviewed BPC-157 in Achilles tendon repair and muscle-to-bone healing, with proposed mechanisms involving EGR-1 gene upregulationa transcription factor important in tendon and ligament repair
